Data Insights
Artificial Intelligence (10)
Big Data (3)
Biosimilars (5)
Blockchain (1)
Cell & Gene Therapy (13)
Chemotherapy (1)
Cloud (1)
Corporate Governance (3)
Covid-19 (5)
Cybersecurity (4)
Digitalization (2)
Easy & Affordable (1)
Electronic Medical Record (EMR) Systems (1)
Environmental Sustainability (6)
Future of Work (2)
Genomics (10)
Health & Wellness (1)
Immuno-oncology (19)
Immunotherapy (1)
Individualism & Expression (1)
Internet of Things (2)
Microbiome (1)
Mobile Health (1)
Nanomedicine (2)
Oncology (4)
Orphan Designated Drugs (4)
Other Innovation Areas (87)
Personalization (1)
Precision and Personalized Medicine (1)
Remote Patient Monitoring (1)
Renewable Energy (1)
Robotics (2)
Small molecules (1)
Smart Hospitals (2)
Social Responsibility (3)
Virtual Care (2)
Showing 4 results out of 4
![](https://pr-fr-solr-b2b-gdm-figaro1.pantheonsite.io/pharmaceutical-technology/wp-content/plugins/wpsolr-pro-gd/wpsolr/core/images/gif-load.gif)
How did the pharmaceutical industry treat orphan designated drugs in Q2 2024 filings?
The global pharmaceutical industry experienced a 7% drop in company filings mentions of orphan designated drugs in Q2 2024 compared...
How orphan designated drugs M&A performed in the pharmaceutical industry in Q1 2024
Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 36 pharmaceutical deals announced in...
Q1 2024 update: orphan designated drugs related private equity activity in the pharmaceutical industry
Analysis of the key themes driving private equity deal activity reveals that orphan designated drugs accounted for 3 pharmaceutical deals...
Who’s posting what? Orphan Designated Drugs related social media posts increased by 9% in the pharma industry in Q1 2023
The global pharma industry experienced a 9% rise in social media posts on orphan designated drugs in Q1 2023 compared...